Effects of exogenous gamma-aminobutyric acid on experimental arrhythmias.
The effects of exogenous gamma-aminobutyric acid (GABA) 10 mg.kg-1 iv in preventing arrhythmias induced by drugs and ischemia were studied in mice, rats, and guinea pigs. It was found that the threshold dose of aconitine inducing arrhythmia in mice and the recovery rate to normal sinus rhythm increased significantly, ED50 of GABA was 5.4-5.8 mg.kg-1. The duration of ventricular tachycardia (VT) induced by aconitine in rats was shortened (P < 0.01). The incidence and the mortality of ventricular fibrillation (VF) in GABA group were decreased to 0/10 vs 6/10 and 5/10 in control, respectively (P < 0.05). The doses of ouabain to induce ectopic beats (EB), VT, VF, and cardiac arrest (CA) in guinea pigs were increased (P < 0.01). The incidence of VF induced by coronary artery ligation in rats was decreased to 0/5 in GABA group vs 4/5 in control group (P < 0.01). The total amount of EB, total time of VT, and VF were 66%, 41%, and 0% of the control group, respectively. The anti-arrhythmic effects of GABA were dose-dependent and as potent as procainamide (10 or 5 mg.kg-1, iv). The results suggest GABA (10 mg.kg-1, iv) may be useful for the prevention of VT and VF.
Wang
L Y
LY
Beijing Heart Lung and Blood Vessel Medical Center, China.
Meng
J R
JR
Wu
T
T
Li
R Z
RZ
He
Y Q
YQ
Zhang
Q B
QB
D000157:Aconitine; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000517:prevention & control*; D005260:Female; D006168:Guinea Pigs; D008297:Male; D051379:Mice; D010042:Ouabain; D011342:Procainamide / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
D005680:gamma-Aminobutyric Acid; D010042:Ouabain; D011342:Procainamide; D000157:Aconitine